Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients-Reference-Cited by-同舟云学术

Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients

Published:2012-01-17 Issue:17 Volume:118 Page:4321-4330
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Christensen Anthony M.,Pauley Jennifer L.,Molinelli Alejandro R.,Panetta John C.,Ward Deborah A.,Stewart Clinton F.,Hoffman James M.,Howard Scott C.,Pui Ching-Hon,Pappo Alberto S.,Relling Mary V.,Crews Kristine R.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference31 articles.

1. Concepts in use of high-dose methotrexate therapy;Treon;Clin Chem,1996

2. Understanding and managing methotrexate nephrotoxicity;Widemann;Oncologist,2006

3. Glucarpidase following high-dose methotrexate: update on development;Patterson;Expert Opin Biol Ther,2010

4. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity;Park;Cancer Res Treat,2005

5. Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy;Schwartz;Oncologist,2007

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating methotrexate toxicity: Examining the therapeutic roles of folinic acid and glucarpidase;British Journal of Clinical Pharmacology;2024-06-18

2. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma;JCO Oncology Practice;2024-06

3. A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK;Health Science Reports;2024-01

4. Methotrexate level discrepancy post‐glucarpidase: A pediatric case series and review of literature;Pediatric Blood & Cancer;2023-12-27

5. Diagnostic, Pathologic, and Therapeutic Considerations for Primary CNS Lymphoma;JCO Oncology Practice;2023-11-15